Supplementary material has been published as submitted. It has not been copyedited, typeset or checked for scientific content by Journal of Rehabilitation Medicine

Table SI. Number of participants, HADS depression scores at 3 and 12 months-

	HADS-Depression	n levels at 12				
	months					
HADS- Depression levels at 3						
months	None (0-7)	Mild (8-10)	Moderate (11-14)	Severe (15-21)	Missing	Total
None (0-7)	185	18	0	0	27	230
Mild (8-10)	10	12	3	0	4	29
Moderate (11-14)	5	3	4	0	1	13
Severe (15-21)	1	0	0	0	0	1
Missing	13	1	2	0	3	19
Total	214	34	9	0	35	

HADS: Hospital Anxiety and Depression scale.

Table SII. Number of participants, HADS anxiety scores at 3 and 12 months. HADS: Hospital Anxiety and Depression scale.

	HADS-Anxiety levels at 12 months					
HADS- Anxiety levels at 3 months	None (0-7)	Mild (8-10)	Moderate (11-14)	Severe (15-21)	Missing	Total
None (0-7)	175	13	6	1	25	220
Mild (8-10)	11	13	0	0	6	30
Moderate (11-14)	3	3	5	1	1	13
Severe (15-21)	1	0	0	1	0	2
Missing	17	3	3	1	3	27
Total	207	32	14	4	35	

HADS: Hospital Anxiety and Depression scale.

Table SIII. Symptoms of anxiety or depression at 3 months. Selection: participants with HADS A and D scores at 3 months.

	N	%
HADS A/D score 0-7	215	77.6
HADS A/D score 8-21	62	22.4
Total	277	100

HADS: Hospital Anxiety and Depression scale.

Table SIV. Symptoms of anxiety or depression at 12 months. Selection: participants with HADS A and D scores at 12 months.

	N	%
HADS A/D score 0-7	195	75.6
HADS A/D score 8-21	63	24.4
Total	258	100

HADS: Hospital Anxiety and Depression scale.

Table SV. Comorbid symptoms of anxiety and depression at 3 months among participants with HADS A and D scores at 3 months.

	N	%
HADS A/D score 0-7	215	77.6
HADS A/D score 8-21	62	22.4
Total	277	100

HADS: Hospital Anxiety and Depression scale.

Table SVI. Comorbid symptoms of anxiety and depression at 12 months among participants with HADS A and D scores at 12 months.

	N	%
HADS A/D score 0-7	195	75.6
HADS A/D score 8-21	63	24.4
Total	258	100

HADS: Hospital Anxiety and Depression scale.

Table SVII. Distribution of the conditions included in the Charlson Comorbidity index – Frequencies and percentages for all included participants.

	Overall (N=292)
Acute myocardial infarction	
No	249 (85.3%)
Yes	43 (14.7%)
Congestive heart failure	
No	287 (98.3%)
Yes	5 (1.7%)
Peripheral vascular disease	
No	288 (98.6%)
Yes	4 (1.4%)
Cerebral vascular disease	
No	248 (84.9%)
Yes	44 (15.1%)
Dementia	
No	290 (99.3%)
Yes	2 (0.7%)
COPD	
No	273 (93.5%)
Yes	19 (6.5%)
Connective tissue disease	, ,
No	274 (93.8%)
Yes	18 (6.2%)
Peptic ulcer disease	10 (0.270)
No.	288 (98.6%)
Yes	4 (1.4%)
Liver disease	. ()
Mean (SD)	0 (0)
Median [Min, Max]	0 [0, 0]
Severe liver disease	0 [0, 0]
No	292 (100%)
Diabetes	232 (10070)
No	238 (81.5%)
Yes	
	54 (18.5%)
Diabetes with complications No	250 (05 60/)
	250 (85.6%)
Yes	42 (14.4%)
Paraplegia	202 (4000)
No	292 (100%)
HIV disease	
No	292 (100%)
Renal disease	
No	284 (97.3%)
Yes	8 (2.7%)
Cancer	
No	245 (83.9%)
Yes	47 (16.1%)
Metastatic cancer	
No	286 (97.9%)
Yes	6 (2.1%)
Charlson comorbidity burden	
0 - None	115 (39.4%)
1 - Low	72 (24.7%)
2-3 - Moderate	73 (25.0%)
4 or more - High	32 (11.0%)

Table SVIII. Follow-up time for included participants at 3 and 12 months. Numbers presented in mean (SD)

Days from discharge to 12 months follow-up 370.71 (70.84)

Days from discharge to 3 months follow-up 107.89 (27.45)